Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Corvus Pharmaceuticals (CRVS) EBIAT (2022 - 2025)

Corvus Pharmaceuticals has reported EBIAT over the past 4 years, most recently at -$12.3 million for Q4 2025.

  • Quarterly results put EBIAT at -$12.3 million for Q4 2025, down 1.72% from a year ago — trailing twelve months through Dec 2025 was -$15.3 million (up 75.47% YoY), and the annual figure for FY2025 was -$15.3 million, up 75.47%.
  • EBIAT for Q4 2025 was -$12.3 million at Corvus Pharmaceuticals, down from -$10.2 million in the prior quarter.
  • Over the last five years, EBIAT for CRVS hit a ceiling of $15.2 million in Q1 2025 and a floor of -$40.2 million in Q3 2024.
  • Median EBIAT over the past 4 years was -$8.1 million (2022), compared with a mean of -$9.1 million.
  • Biggest five-year swings in EBIAT: tumbled 570.28% in 2024 and later surged 366.5% in 2025.
  • Corvus Pharmaceuticals' EBIAT stood at -$9.8 million in 2022, then soared by 32.17% to -$6.7 million in 2023, then crashed by 82.07% to -$12.1 million in 2024, then decreased by 1.72% to -$12.3 million in 2025.
  • The last three reported values for EBIAT were -$12.3 million (Q4 2025), -$10.2 million (Q3 2025), and -$8.0 million (Q2 2025) per Business Quant data.